Page 162 - Read Online
P. 162
Dastidar et al. Vessel Plus 2020;4:14 I http://dx.doi.org/10.20517/2574-1209.2019.36 Page 9 of 29
Figure 3. Schematic representation of NO generating tumour vasculature targeted drug delivery systems. Copper ion-chelated
porphyrin triggers tumour vasculature specific release of NO causing local vasodilation, whereas RGD peptide causes α v β 3 mediated
tumour cell-specific nanoparticle uptake. The drug is released specifically within the cancer cells where the cytoplasmic levels of GSH is
higher than normal cells. NO: nitric oxide; GSH: glutathione; RSNO: S-Nitroso alkane NP: nanoparticle; RGD: arginylglycylaspartic acid
